Brett J Theeler1, Benjamin Ellezam2, Isaac Melguizo-Gavilanes3, John F de Groot4, Anita Mahajan5, Kenneth D Aldape6, Janet M Bruner6, Vinay K Puduvalli7. 1. Department of Neurology and John P. Murtha Cancer Center, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Building 19, Bethesda, MD 20889, United States. Electronic address: btheeler@hotmail.com. 2. Department of Pathology, CHU Sainte-Justine, Universite de Montreal, 3175 Cote-Ste-Catherine Rd, Montreal, Quebec H3TIC5, Canada. 3. Neuro-Oncology Associates at Baylor Charles A. Sammons Cancer Center, 3410 Worth Street, Suite 820, Dallas, TX 75246, United States. 4. Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit Number: 431, Houston, TX 77030, United States. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States. 6. Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States. 7. Division of Neuro-oncology, The Ohio State University Comprehensive Cancer Center, 320 W 10th Avenue, Starling Loving Hall Suite M410, Columbus, OH 43210, United States.
Abstract
BACKGROUND: Brainstem gliomas are rare in adults and overall have superior survival outcomes compared to pediatric brainstem gliomas. PATIENTS AND METHODS: We conducted a retrospective data and tissue analysis of all adult patients (≥ 18 years old) with World Health Organization (WHO) Grade II, III, and IV brainstem gliomas in the University of Texas MD Anderson Cancer Center institutional database from 1990 to 2012. RESULTS: We identified 143 cases in adults ages 18 and over. There were 28 glioblastomas, 43 anaplastic astrocytomas, 15 diffuse astrocytomas, and 11 gliomas not otherwise specified, and in 46 cases the diagnosis was made radiographically. 128 (89.5%) cases were classified radiographically as diffuse and of the focal tumors, 9 of the 15 were WHO Grade III or IV tumors. Increasing tumor grade and contrast enhancement were associated with significantly reduced overall survival. The median overall survival for the entire cohort was 32.1 months similar to previously published studies. Two of 25 grade II and III tumors, and 1 of 17 glioblastomas had IDH1 mutations on immunohistochemical testing. Nine cases had sufficient tissue for mutation profiling, 1 case had a BRAF V600E mutation and 2 had 2 PIK3CA mutations. CONCLUSIONS: Survival outcomes for adult WHO Grade II to IV brainstem gliomas were similar to supratentorial IDH1 wild-type tumors of similar grade and histology. Potentially actionable mutations can be identified from small biopsy samples in a subset of adult brainstem gliomas. Published by Elsevier B.V.
BACKGROUND:Brainstem gliomas are rare in adults and overall have superior survival outcomes compared to pediatric brainstem gliomas. PATIENTS AND METHODS: We conducted a retrospective data and tissue analysis of all adult patients (≥ 18 years old) with World Health Organization (WHO) Grade II, III, and IV brainstem gliomas in the University of Texas MD Anderson Cancer Center institutional database from 1990 to 2012. RESULTS: We identified 143 cases in adults ages 18 and over. There were 28 glioblastomas, 43 anaplastic astrocytomas, 15 diffuse astrocytomas, and 11 gliomas not otherwise specified, and in 46 cases the diagnosis was made radiographically. 128 (89.5%) cases were classified radiographically as diffuse and of the focal tumors, 9 of the 15 were WHO Grade III or IV tumors. Increasing tumor grade and contrast enhancement were associated with significantly reduced overall survival. The median overall survival for the entire cohort was 32.1 months similar to previously published studies. Two of 25 grade II and III tumors, and 1 of 17 glioblastomas had IDH1 mutations on immunohistochemical testing. Nine cases had sufficient tissue for mutation profiling, 1 case had a BRAFV600E mutation and 2 had 2 PIK3CA mutations. CONCLUSIONS: Survival outcomes for adult WHO Grade II to IV brainstem gliomas were similar to supratentorial IDH1 wild-type tumors of similar grade and histology. Potentially actionable mutations can be identified from small biopsy samples in a subset of adult brainstem gliomas. Published by Elsevier B.V.
Authors: Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape Journal: Cancer Cell Date: 2010-04-15 Impact factor: 31.743
Authors: Christian Hartmann; Bettina Hentschel; Wolfgang Wick; David Capper; Jörg Felsberg; Matthias Simon; Manfred Westphal; Gabriele Schackert; Richard Meyermann; Torsten Pietsch; Guido Reifenberger; Michael Weller; Markus Loeffler; Andreas von Deimling Journal: Acta Neuropathol Date: 2010-11-19 Impact factor: 17.088
Authors: J S Guillamo; A Monjour; L Taillandier; B Devaux; P Varlet; C Haie-Meder; G L Defer; P Maison; J J Mazeron; P Cornu; J Y Delattre Journal: Brain Date: 2001-12 Impact factor: 13.501
Authors: Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes Journal: Cancer Cell Date: 2010-01-19 Impact factor: 31.743
Authors: Martin J van den Bent; Hendrikus J Dubbink; Marc Sanson; Cathleen R van der Lee-Haarloo; Monika Hegi; Judith W M Jeuken; Ahmed Ibdaih; Alba A Brandes; Martin J B Taphoorn; Marc Frenay; Denis Lacombe; Thierry Gorlia; Winand N M Dinjens; Johan M Kros Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544
Authors: Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: M Labussière; A Idbaih; X-W Wang; Y Marie; B Boisselier; C Falet; S Paris; J Laffaire; C Carpentier; E Crinière; F Ducray; S El Hallani; K Mokhtari; K Hoang-Xuan; J-Y Delattre; M Sanson Journal: Neurology Date: 2010-04-28 Impact factor: 11.800
Authors: Nanne K Kloosterhof; Linda B C Bralten; Hendrikus J Dubbink; Pim J French; Martin J van den Bent Journal: Lancet Oncol Date: 2010-07-07 Impact factor: 54.433
Authors: T Vosecka; A Vicha; T Zelinka; P Jencova; K Pacak; J Duskova; J Benes; A Guha; L Stanek; M Kohoutova; Z Musil Journal: Neoplasma Date: 2017 Impact factor: 2.575
Authors: Panagiotis Kerezoudis; Anshit Goyal; Victor M Lu; Mohammed Ali Alvi; Mohamad Bydon; Sani H Kizilbash; Terry C Burns Journal: J Neurooncol Date: 2019-12-24 Impact factor: 4.130
Authors: Rouzbeh Banan; Arash Akbarian; Majid Samii; Amir Samii; Helmut Bertalanffy; Ulrich Lehmann; Christian Hartmann; Roland Brüning Journal: PLoS One Date: 2021-08-04 Impact factor: 3.240